Obecabtagene autoleucel (Aucatzyl)
Customize your policy alerts
Sign up for Baylor Scott & White Health Plan Policy 315 alerts
Get alerted when Policy 315 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity review for obecabtagene autoleucel used to treat adult members with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It applies across lines of business unless otherwise specified by the member's benefit plan, with separate Medicare and Medicaid coverage guidance noted.
Added exclusion of members with prior treatment using CAR-T cell immunotherapy.
Updated the applicable HCPCS code for obecabtagene autoleucel.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.